|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5030453A
(en)
|
1983-03-24 |
1991-07-09 |
The Liposome Company, Inc. |
Stable plurilamellar vesicles
|
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
|
US5891467A
(en)
|
1997-01-31 |
1999-04-06 |
Depotech Corporation |
Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
|
|
US6017926A
(en)
|
1997-12-17 |
2000-01-25 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
KR20010033248A
(ko)
|
1997-12-17 |
2001-04-25 |
폴락 돈나 엘. |
인테그린 수용체 길항제
|
|
CA2361201A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
DE60040274D1
(de)
|
1999-03-10 |
2008-10-30 |
Phogen Ltd |
Verabreichung von nukleinsäuren und proteinen an zellen
|
|
US6309401B1
(en)
|
1999-04-30 |
2001-10-30 |
Vladimir Redko |
Apparatus and method for percutaneous implant of a paddle style lead
|
|
EP1272630A2
(en)
|
2000-03-16 |
2003-01-08 |
Genetica, Inc. |
Methods and compositions for rna interference
|
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
|
US20080188430A1
(en)
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
|
EP1399189A1
(en)
|
2001-06-11 |
2004-03-24 |
Universite De Montreal |
Compositions and methods for enhancing nucleic acid transfer into cells
|
|
JP5170934B2
(ja)
|
2001-08-16 |
2013-03-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用
|
|
DE10230997A1
(de)
|
2001-10-26 |
2003-07-17 |
Ribopharma Ag |
Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
US20050008617A1
(en)
|
2002-09-28 |
2005-01-13 |
Massachusetts Institute Of Technology |
Compositions and methods for delivery of short interfering RNA and short hairpin RNA
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
EP1585756B1
(en)
|
2002-11-26 |
2010-04-21 |
University of Massachusetts |
Delivery of sirnas
|
|
CA2532228C
(en)
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
EP1660657A1
(en)
|
2003-08-28 |
2006-05-31 |
Novartis AG |
Interfering rna duplex having blunt-ends and 3'-modifications
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
WO2005116204A1
(ja)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
|
|
EP1791567B1
(en)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
KR101629017B1
(ko)
|
2007-05-22 |
2016-06-10 |
아크투루스 쎄라퓨틱스, 인크. |
히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체
|
|
EP2186528B1
(en)
|
2007-08-06 |
2014-03-19 |
Senju Pharmaceutical Co., Ltd. |
Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
|
|
ES2535419T3
(es)
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
CN102026671B
(zh)
*
|
2008-03-14 |
2014-09-03 |
Visen医药公司 |
整联蛋白靶向试剂及使用其的体内和体外成像方法
|
|
US8067178B2
(en)
|
2008-03-14 |
2011-11-29 |
Genomic Health, Inc. |
Gene expression markers for prediction of patient response to chemotherapy
|
|
DK2265283T3
(da)
|
2008-03-18 |
2014-10-20 |
Seattle Genetics Inc |
Auristatin-lægemiddel-linker-konjugater
|
|
AU2009232355A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
|
KR101728655B1
(ko)
|
2008-12-18 |
2017-04-19 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
CA3009891C
(en)
|
2009-12-23 |
2020-09-15 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
SI2539451T1
(sl)
|
2010-02-24 |
2016-04-29 |
Arrowhead Research Corporation |
Sestavki za ciljano dostavo sirna
|
|
KR101223660B1
(ko)
|
2010-05-20 |
2013-01-17 |
광주과학기술원 |
ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
AU2011343664B2
(en)
|
2010-12-17 |
2015-10-08 |
Arrowhead Pharmaceuticals, Inc. |
Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
|
|
CA3131967A1
(en)
|
2010-12-29 |
2012-07-05 |
F. Hoffman-La Roche Ag |
Small molecule conjugates for intracellular delivery of nucleic acids
|
|
WO2012174224A2
(en)
|
2011-06-17 |
2012-12-20 |
Calando Pharmaceuticals, Inc. |
Methods for administering nucleic acid-based therapeutics
|
|
WO2013032829A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
CA2842041A1
(en)
|
2012-04-18 |
2013-10-24 |
Arrowhead Research Corporation |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
CN105247051A
(zh)
|
2013-02-28 |
2016-01-13 |
箭头研究公司 |
治疗epas1相关疾病的有机组合物
|
|
US9504747B2
(en)
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
WO2015021092A1
(en)
|
2013-08-07 |
2015-02-12 |
Arrowhead Research Corporation |
Polyconjugates for delivery of rnai triggers to tumor cells in vivo
|
|
WO2016149020A1
(en)
|
2015-03-17 |
2016-09-22 |
Arrowhead Research Corporation |
Rna interference agents
|
|
AR104754A1
(es)
|
2015-05-29 |
2017-08-09 |
Arrowhead Pharmaceuticals Inc |
Agentes de unión de tetrapéptido escindibles biológicamente
|
|
JP7420727B2
(ja)
|
2018-02-17 |
2024-01-23 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
トリアルキン結合剤及び使用方法
|
|
SG11202009734VA
(en)
|
2018-04-27 |
2020-11-27 |
Arrowhead Pharmaceuticals Inc |
Integrin targeting ligands and uses thereof
|